BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 18494804)

  • 1. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repaglinide in combination therapy.
    Moses R
    Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results.
    Reboussin DM; Goff DC; Lipkin EW; Herrington DM; Summerson J; Steffes M; Crouse RJ; Jovanovic L; Feinglos MN; Probstfield JL; Banerji MA; Pettitt DJ; Williamson J
    Diabet Med; 2004 Oct; 21(10):1082-9. PubMed ID: 15384954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
    Davies MJ; Thaware PK; Tringham JR; Howe J; Jarvis J; Johnston V; Kitchener DL; Skinner TC; McNally PG; Lawrence IG
    Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of costs for four oral antidiabetic regimens within a managed care population.
    Stockl K; Vanderplas AM; Nicklasson L
    Manag Care Interface; 2003 Jul; 16(7):31-6. PubMed ID: 12908215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination treatment with insulin and metformin in type 2 diabetes. Improves glycemic control and prevents weight gain].
    Hermann LS; Melander A
    Lakartidningen; 1999 Dec; 96(50):5616-9. PubMed ID: 10643226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.
    Guay DR
    Pharmacotherapy; 1998; 18(6):1195-204. PubMed ID: 9855316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metformin. Mode of action and effect of monotherapy and combination therapy on glucose metabolism in type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2025-8. PubMed ID: 11985000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
    Kokić S; Buković D; Radman M; Capkun V; Gabrić N; Lesko V; Karelović D; Stancerić T
    Coll Antropol; 2003 Jun; 27(1):181-7. PubMed ID: 12974145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.
    Stewart MW; Cirkel DT; Furuseth K; Donaldson J; Biswas N; Starkie MG; Phenekos C; Hamann A
    Diabet Med; 2006 Oct; 23(10):1069-78. PubMed ID: 16978370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus.
    Shapiro MS; Abrams Z; Lieberman N
    Isr Med Assoc J; 2005 Feb; 7(2):75-7. PubMed ID: 15729954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.